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Abstract: Due to practical and ethical concerns associated with human experimentation, animal models have been
essential in cancer research. However, the average rate of successful translation from animal models to clinical
cancer trials is less than 8%. Animal models are limited in their ability to mimic the extremely complex process of
human carcinogenesis, physiology and progression. Therefore the safety and efficacy identified in animal studies is
generally not translated to human trials. Animal models can serve as an important source of in vivo information, but
alternative translational approaches have emerged that may eventually replace the link between in vitro studies and
clinical applications. This review summarizes the current state of animal model translation to clinical practice, and
offers some explanations for the general lack of success in this process. In addition, some alternative strategies to
the classic in vivo approach are discussed.
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Introduction
Prior to embarking on cancer drug trials, pharmaceutical companies and independent investigators conduct extensive pre-clinical studies.
In vitro (test tube or cell culture) and in vivo (animal experiments) studies examine preliminary
efficacy, toxicity and pharmacokinetics. Early in
vivo testing specifically aims to demonstrate
safety, which assists investigators to determine
whether a candidate drug has scientific merit to
justify further development. Both the Food and
Drug Administration (FDA) and Health Canada
require that animal tests be conducted before
humans are exposed to a new molecular entity
[1, 2].
The ultimate goal of cancer researchers is to
translate scientific findings into practical clinical applications. Experimental discoveries are
thought to begin at “the bench” with basic
research, progress through pre-clinical animal
studies, then show therapeutic efficacy in
human clinical trials. Although animal models
continue to play a large role in the evaluation of
efficacy and safety of new cancer interventions,
genetic, molecular, and physiological limita-

tions often hinder their utility. Despite successful pre-clinical testing, 85% of early clinical trials for novel drugs fail; of those that survive
through to phase III, only half become approved
for clinical use [3]. The largest proportion of
these failures occurs in trials for cancer drugs
[4]. Furthermore, fewer than one in five cancer
clinical trials find their way to the peer-reviewed
literature, generally due to negative findings [5].
Although logistical and study design issues are
often identified as the root cause of clinical trial
failures, most futilities in fact originate from
molecular mechanisms of the drug(s) tested
[6].
The overall result is that promising pre-clinical
animal studies that require extensive resources
both in time and money rarely translate into
successful treatments. This review provides a
critical evaluation of pre-clinical animal models
and their role in translation to clinical practice
for cancer patients.
Limitations of animal models in cancer research
Animal models have not been validated as a
necessary step in biomedical research in the
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scientific literature [7]. Instead, there is a growing awareness of the limitations of animal
research and its inability to make reliable predictions for human clinical trials [8]. Indeed,
animal studies seem to overestimate by about
30% the likelihood that a treatment will be
effective because negative results are often
unpublished [9]. Similarly, little more than a
third of highly cited animal research is tested
later in human trials [10]. Of the one-third that
enter into clinical trials, as little as 8% of drugs
pass Phase I successfully [11].
The major pre-clinical tools for new-agent
screening prior to clinical testing are experimental tumors grown in rodents. Although mice
are most commonly used, they are actually
poor models for the majority of human diseases [12]. Crucial genetic, molecular, immunologic and cellular differences between humans
and mice prevent animal models from serving
as effective means to seek for a cancer cure
[13]. Among 4,000+ genes in humans and
mice, researchers found that transcription factor binding sites differed between the species
in 41% to 89% of cases [14]. In many cases,
mouse models serve to replicate specific processes or sets of processes within a disease
but not the whole spectrum of physiological
changes that occur in humans in the disease
setting [15].
The failure to translate from animals to humans
is likely due in part to poor methodology and
failure of the models to accurately mimic the
human disease condition. The core of the problem may be rooted in the animal modeling
itself. Unlike in human clinical trials, no bestpractice standards exist for animal testing [14].
Moreover, the laboratory environment can have
a significant effect on experimental results, as
stress is a common factor in caged mice [16]. It
has been recommended that therapeutic
agents should not only be evaluated in rodents,
but also in higher animal species, and that randomization and outcomes assessor blinding
should be performed. In addition, experiments
should be designed in both genders and in different age groups of animals and all data, both
positive and negative, should be published [3].
Notable examples of failed clinical cancer trials initiated due to successful animal models
A well-known example of a successful animal
model that did not translate into clinical trials is
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the TGN1412 trial [17]. The drug TGN1412,
developed by the company TeGenero, was
described as an immunomodulatory humanized agonistic anti-CD28 monoclonal antibody
developed for the treatment of immunological
diseases such as multiple sclerosis, rheumatoid arthritis and certain cancers. Before conducting human trials, TGN1412 was tested on
different animals including mice, to ensure
safety and efficacy in preclinical animal models
[17]. These toxicity studies demonstrated that
doses hundred times higher than that administered to humans did not induce any toxic reactions. In the first human clinical trials of
TGN1412, the drug caused catastrophic systemic organ failure in patients, despite being
administered at a sub-clinical dose that was
500 times lower than the dose found safe in
animal studies [18].
In a recent report, a Phase II randomized clinical trial of the Hedgehog pathway antagonist
IPI-926 (saridegib) in patients with advanced
chondrosarcoma was stopped early for futility
[19]. The Hedgehog pathway is dysregulated in
a variety of solid tumors and provides key
growth and survival signals to tumor cells.
Mutations resulting in constitutive Hedgehog
signaling are causal in cartilage tumors such as
chondrosarcoma [20]. The Phase II clinical trial
for IPI-926 translated from a successful animal
model of IPI-926 on a malignant solid brain
tumor [21]. IPI-926 treated mice with the
advanced brain tumors gained a fivefold
increase in survival [21]. However, IPI-926
showed no effect compared to placebo in the
human trial [19]. Therefore even a targeted
molecular approach did not result in clinical
efficacy despite remarkable success in mice.
Matrix metalloproteinases (MMPs) are a family
of zinc-dependent proteinases involved in the
degradation and remodeling of extracellular
matrix proteins and are associated with the
tumorigenic process. MMPs promote tumor
invasion and metastasis, regulating host
defense mechanisms and normal cell function
[22]. Cancer and arthritis were once regarded
as the prime indications for the use of MMP
inhibitors (MMPIs) and results from multiple
animal studies indeed indicated that MMP inhibition would be an effective therapeutic
approach in the management of cancer and
other diseases [15]. However, multiple failed
clinical trials in humans have had the effect of
Am J Transl Res 2014;6(2):114-118
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seriously reducing interest in MMP inhibition as
a valid therapeutic option [22].
Among the more-than 16 MMPIs that progressed to clinical testing, only Periostat (doxycycline hyclate, a nonspecific MMPI) has been
approved for clinical use in periodontal disease
[15]. The serious safety problems in clinical trials have been attributed to poor selectivity of
the MMPIs, poor target validation for the targeted therapy and poorly defined predictive
preclinical animal models for safety and efficacy [23]. The failure and indeed resulting damage of all anti-MMP drugs in clinical trials indicated that MMPs as a class have useful
functions in normal tissue, and therefore inhibition would result in toxicities in the human host
not identified in the animal models in which
they were tested.
Therapeutic cancer vaccines are becoming
increasingly popular in the approach to cancer
treatment. The concept of stimulating the
body’s immune system to fight tumors, representing an alternative approach to the use of
traditional cytotoxic cancer therapies, is indeed
compelling [24]. A typical therapeutic vaccine
against cancer contains a cancer-specific peptide, or protein fragment, that is injected under
the skin of either the tested animals or humans.
It is assumed that the immune system would
recognize the peptide as something to be
attacked and boosts the population of cancerfighting T-cells in the bloodstream [25]. These
vaccines must first be tested in animals to confirm efficacy prior to entering into human clinical trials [26]. In the particular case of cancer,
preclinical animal models have provided new
knowledge regarding vaccine-induced immune
responses and the central importance of T cellmediated cellular responses in cancer treatment [25].
Although therapeutic cancer vaccines have
been effective in initiating the immune
response in animal models, they have produced mixed results in human clinical trials. In
a recent review article, it was reported that out
of 23 Phase II/III clinical trials testing 17 distinct therapeutic anticancer vaccines, 18 of
these studies had failed [27]. Some examples
are Merck’s Stimuvax (failed a phase III trial on
non-small cell lung cancer) [28], GlaxoSmithKline’s MAGE-A3 (failed a phase III melanoma trial) [29], Vical’s Allovectin (failed a
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phase III metastatic melanoma trial) [30], and
KAEL-GemVax’s TeloVac (failed a phase III pancreatic cancer trial) [31]. It has been postulated
that most of the cancer vaccine trials have
failed due to elevated levels of circulating
immunosuppressive cytokines and various
immunological checkpoints in humans that
may not be present in rodents [25].
Critical re-evaluation of animal models and
alternative strategies
Despite the general lack of success in translating animal models to clinical studies, animals
are still prevalently used in laboratories all over
the world to test the safety, toxicity and effectiveness of drugs [32]. Animal models have
been essential in cancer research for obvious
practical and ethical concerns associated with
human experimentation. Animal research is
similar to in vitro assays, epidemiological investigations, and computer simulations. All
attempt to derive probabilistic knowledge in
one context that will generalize to humans. All
are forms of modeling that will map onto the
whole population with less than perfect precision and predict with even less precision the
fate of any individual. Notwithstanding, these
methods risk missing some important knowledge, or risk finding knowledge that doesn’t
hold up in the clinical setting even to a point
that is actually harmful once widely deployed.
Ultimately, we come into the question as to
whether we should spare resources and bypass
animal models to evaluate therapy in humans
directly. In the last decade, the FDA and the
European Medicines Agency introduced guidelines for testing very small ‘micro-doses’ of
drugs in humans [33]. These are concentrations less than a one-hundredth of the therapeutic dose. Because the concentrations are
so low, the drugs can be tested in a small number of patients without the level of safety data
normally required before a phase I study. These
early ‘phase 0’ studies collect human data
quickly by showing how the drug is distributed
and metabolized in the body, and whether it
hits the right molecular target. Approximately
one-quarter of the molecules entering clinical
trials fail due to pharmacological issues such
as lack of absorption or penetration into the
target organ [33]. With a direct test in humans,
pharmaceuticals can determine earlier whether the drug is worth investing both time and
Am J Transl Res 2014;6(2):114-118
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money into clinical research. Phase 0 trials may
be small in scope, but they require very sensitive tests to detect the minute quantities of the
drug in the body and possibly its mechanism of
action.
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Aside from phase 0 studies, a wide range of
alternatives to animal-based preclinical
research has emerged. These include epidemiological studies, autopsies, in vitro studies, in
silico computer modelling, “human organs on a
chip” - creating living systems on chips by mimicking a micro- biological environment with cells
of a certain organ implanted onto silicon and
plastic chips [34], and “microfluidic chips” automation of over a hundred cell cultures or
other experiments on a tiny rubbery silicone
integrated circuit with miniscule plumbing [35].
The National Institutes of Health of the United
States suspended all new grants for biomedical
and behavioural research on chimpanzees
after an expert committee concluded that such
research was unnecessary [36]. Furthermore,
the US National Research Council recommends
that animal model based tests be replaced as
soon as possible with in vitro human cell-based
assays, in silico models, and an increased
emphasis on epidemiology [37].
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basic translational model in the preclinical setting in elucidating key biochemical and physiologic processes of cancer onset and propagation in a living organism. Experimental tumors
raised in animals, particularly in rodents, constitute the major preclinical tool of evaluating
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drugs screening before clinical testing. The
power of the animal models to predict clinical
efficacy is a matter of dispute due to weaknesses in faithfully mirroring the extremely complex
process of human carcinogenesis. The vast
majority of agents that are found to be successful in animal models do not pan out in human
trials. Differences in physiology, as well as variations in the homology of molecular targets
between mice and humans, may lead to translational limitations. Even though animal models
still remain a unique source of in vivo information, other emerging translational alternatives
may eventually replace the link between in vitro
studies and clinical applications.
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